Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Leo's eczema prospect hits primary endpoint in phase 2b
Leo shared phase 2b data on temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint.
Nick Paul Taylor
May 9, 2025 7:30am
GSK posts phase 3 itch data as it closes in on FDA approval
May 8, 2025 8:50am
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
May 7, 2025 10:00am
Marea rises toward phase 2b after posting cholesterol data
May 7, 2025 8:25am
PTC and Novartis’ Huntington's data fail to convince investors
May 6, 2025 7:25am
Aldeyra posts hit, miss for dry eye drug, plans FDA filing
May 6, 2025 7:05am
